CAMBRIDGE, U.K.—Clinical-stage biopharmaceutical company Celyad
recently inked an exclusive agreement with Horizon Discovery Group plc
to gain access to the latter’s shRNA technology, which Celyad will leverage to engineer its second non-gene-edited allogeneic platform. Financial details were not disclosed.
“We are excited to have the opportunity to leverage Horizon’s shRNA platform to further advance our pioneering approach to non-gene-edited allogeneic CAR-T cells,” commented Dr. Christian Homsy, CEO of Celyad. “Celyad is committed to rapidly advancing its allogeneic program based on highly promising preclinical data which will be presented at SITC. These data provide proof of concept for our shRNA based non-gene-edited allogeneic approach. In addition to very promising preclinical data, our allogeneic approach is also strengthened by Celyad’s strong patent estate in the U.S., which broadly covers the use of allogeneic CAR-T using cells that are TCR inhibited or suppressed by any means.”